Medication-Assisted Treatment (MAT) Grants
Federal and state grants fund medication-assisted treatment (MAT) programs, opioid treatment programs, and evidence-based medication-supported addiction recovery. Find funding for opioid treatment clinics, primary care practices, healthcare systems, and organizations expanding access to methadone, buprenorphine, and other MAT modalities.
Types of Medication-Assisted Treatment Grants
MAT Clinic & Program Operations
Grants supporting medication-assisted treatment clinics, opioid treatment programs, and operational funding for MAT services.
- • Opioid treatment program grants
- • MAT clinic operations and staffing
- • Methadone maintenance programs
- • Buprenorphine treatment clinics
Primary Care MAT Integration
Funding for primary care practices and healthcare systems integrating MAT into routine care.
- • Primary care buprenorphine programs
- • Integrated addiction medicine services
- • Office-based opioid treatment (OBOT)
- • Medication-assisted treatment in primary care
MAT Expansion & Access
Grants expanding MAT capacity, reducing barriers, and improving access to treatment.
- • Medication-assisted treatment expansion grants
- • Opioid epidemic response funding
- • Rural MAT access expansion
- • MAT capacity building initiatives
Workforce & Training
Funding for MAT provider training, workforce development, and clinical capacity building.
- • MAT provider training programs
- • Addiction medicine education grants
- • Buprenorphine waiver training
- • Clinical staff development in MAT
How to Access Medication-Assisted Treatment Grants
- Verify MAT Program Status: Ensure your organization operates or is licensed to operate an opioid treatment program (OTP) or has providers with buprenorphine waivers.
- Identify Federal Funding Sources: SAMHSA, NIDA, and HRSA are primary MAT funders. SAMHSA offers grants directly to treatment programs; NIDA funds research-based MAT innovations.
- Check State-Specific Programs: Most states have MAT expansion grants, opioid response funding, and Medicaid-supported MAT expansion initiatives.
- Assess Organizational Capacity: Document existing MAT clients, provider qualifications, clinical infrastructure, and capacity for program expansion.
- Prepare Clinical Documentation: Gather retention rates, treatment outcomes, medication dispensing procedures, and patient demographics.
- Submit Through Proper Channels: Federal grants through grants.gov; state grants through state health/substance abuse agencies.
Major Funding Sources for MAT Programs
SAMHSA (Substance Abuse & Mental Health Services Administration)
Primary federal funder of medication-assisted treatment. Provides grants for OTP operations, MAT expansion, and evidence-based treatment.
NIDA (National Institute on Drug Abuse)
Funds MAT research, innovative treatment approaches, and program evaluation. Supports novel MAT delivery models and outcomes research.
HRSA (Health Resources and Services Administration)
Funds primary care MAT integration, including community health centers and rural health clinics offering buprenorphine treatment.
CDC Opioid Response Grants
Opioid epidemic response funding emphasizing MAT as evidence-based treatment. Highest priority for states with significant opioid addiction burden.
State Health Departments
State substance abuse agencies, Medicaid programs, and opioid response initiatives fund local MAT programs and expansion.
Medication-Assisted Treatment Modalities
Methadone Maintenance
Long-acting synthetic opioid agonist. Traditional gold-standard treatment for opioid addiction, delivered through licensed opioid treatment programs (OTPs).
- • Daily supervised dosing
- • High retention rates
- • Requires OTP licensing
- • Highest cost per patient
Buprenorphine Treatment
Partial opioid agonist with ceiling effect. Can be prescribed in office-based settings by physicians with buprenorphine waivers.
- • Office-based delivery
- • Lower overdose risk
- • Requires physician waiver
- • Growing in primary care
Naltrexone (Injectable)
Opioid antagonist available as extended-release injection. Blocks opioid effects and reduces cravings.
- • Monthly injections
- • Office-based delivery
- • Requires full detoxification
- • Growing pharmaceutical support
Combined Approaches
Integration with psychosocial services, counseling, peer support, and wraparound services for comprehensive recovery.
- • Integrated behavioral health
- • Peer support services
- • Case management
- • Employment support
Key Factors for MAT Grant Success
Clinical Excellence
- ✓ Licensed OTP or waivered providers
- ✓ Documented treatment outcomes
- ✓ High patient retention rates
- ✓ Evidence-based protocols
Organizational Capacity
- ✓ Experienced leadership
- ✓ Financial stability
- ✓ Qualified clinical staff
- ✓ Infrastructure for expansion
Frequently Asked Questions About MAT Grants
What's the difference between SAMHSA and NIDA MAT funding? +
SAMHSA funds operational treatment programs and direct service delivery grants. NIDA funds research and evidence-based innovation in MAT. Most organizations seek SAMHSA operational grants; NIDA is better for research-focused programs.
Do I need to be a licensed OTP to receive MAT funding? +
For methadone programs, yes - OTP licensing is required. For buprenorphine programs, you need physicians with active buprenorphine waivers but don't necessarily need OTP licensing. Primary care practices and community health centers can deliver buprenorphine without OTP status.
What outcome metrics do MAT grant reviewers prioritize? +
Patient retention in treatment (high retention = success), abstinence/reduced use, employment/education engagement, housing stability, reduced criminal justice involvement, and family reunification. Funders want data showing lasting recovery outcomes, not just program participation.
How much funding is available for MAT program expansion? +
SAMHSA grants typically range from $100,000 to $1,000,000+ annually for 3-5 years. State opioid response grants vary widely. Total funding landscape: billions available across federal and state programs focused on MAT as opioid epidemic response.
Can community health centers apply for MAT grants? +
Yes. Community health centers (CHCs) are prioritized for some MAT grants, especially HRSA funding. CHCs can deliver buprenorphine, integrate MAT into primary care, and access federal and state opioid response funding.
Available Medication-Assisted Treatment Grants
No specific medication-assisted treatment grants found in our current database. We recommend searching our full grants database or contacting SAMHSA and your state health department for additional MAT funding opportunities.
Browse All Grants →